Warning! GuruFocus detected
4 Severe warning signs
with 7AC.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Acarix AB
ISIN : SE0009268717
Compare
Compare
Traded in other countries / regions
ACARIX.SwedenACIXF.USA7AC.Germany IPO Date
2016-12-30Description
Acarix AB is a Swedish medical technology company that develops innovative solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. The CADScor System uses advanced acoustics and AI technology to non-invasively rule out CAD in less than 10 minutes, with at least 96 percent certainty.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.94 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 16.42 | |||||
| Beneish M-Score | -1.31 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -32.7 | |||||
| 3-Year EBITDA Growth Rate | 38.3 | |||||
| 3-Year EPS without NRI Growth Rate | 40.6 | |||||
| 3-Year FCF Growth Rate | 37.7 | |||||
| 3-Year Book Growth Rate | -40.1 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 199.09 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 16 | |||||
| 9-Day RSI | 33.68 | |||||
| 14-Day RSI | 41.27 | |||||
| 3-1 Month Momentum % | -11.86 | |||||
| 6-1 Month Momentum % | -32.94 | |||||
| 12-1 Month Momentum % | 0.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.94 | |||||
| Quick Ratio | 12.54 | |||||
| Cash Ratio | 10.66 | |||||
| Days Inventory | 3938.64 | |||||
| Days Sales Outstanding | 149.84 | |||||
| Days Payable | 1824.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -51.7 | |||||
| Shareholder Yield % | -35.86 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 90.2 | |||||
| Operating Margin % | -1070.02 | |||||
| Net Margin % | -1066.98 | |||||
| FCF Margin % | -1037.06 | |||||
| ROE % | -96.16 | |||||
| ROA % | -84.28 | |||||
| ROIC % | -243.21 | |||||
| 3-Year ROIIC % | 20.9 | |||||
| ROC (Joel Greenblatt) % | -1462.04 | |||||
| ROCE % | -95.62 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 2.38 | |||||
| PS Ratio | 30.86 | |||||
| PB Ratio | 3.04 | |||||
| Price-to-Tangible-Book | 1.31 | |||||
| EV-to-EBIT | -3.14 | |||||
| EV-to-EBITDA | -3.3 | |||||
| EV-to-Revenue | 33.26 | |||||
| EV-to-FCF | -3.3 | |||||
| Price-to-GF-Value | 1.31 | |||||
| Price-to-Net-Current-Asset-Value | 1.31 | |||||
| Earnings Yield (Greenblatt) % | -31.91 | |||||
| FCF Yield % | -27.17 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Acarix AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.545 | ||
| EPS (TTM) (€) | -0.007 | ||
| Beta | -0.39 | ||
| 3-Year Sharpe Ratio | 0.18 | ||
| 3-Year Sortino Ratio | 0.28 | ||
| Volatility % | 105.12 | ||
| 14-Day RSI | 41.27 | ||
| 14-Day ATR (€) | 0.005238 | ||
| 20-Day SMA (€) | 0.0188 | ||
| 12-1 Month Momentum % | 0.59 | ||
| 52-Week Range (€) | 0.0113 - 0.0461 | ||
| Shares Outstanding (Mil) | 1,063.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Acarix AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Acarix AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Acarix AB Frequently Asked Questions
What is Acarix AB(FRA:7AC)'s stock price today?
The current price of FRA:7AC is €0.01. The 52 week high of FRA:7AC is €0.05 and 52 week low is €0.01.
When is next earnings date of Acarix AB(FRA:7AC)?
The next earnings date of Acarix AB(FRA:7AC) is 2025-05-12.
Does Acarix AB(FRA:7AC) pay dividends? If so, how much?
Acarix AB(FRA:7AC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers